as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences reported strong FY26 results with consolidated net profit after tax of Rs 647.51 crore, up 72.8% from Rs 374.67 crore in FY25. Revenue from operations grew 8.2% to Rs 3,129.42 crore. The company declared an interim dividend of Rs 7.21 per share (721%) for FY27. An exceptional item of Rs 17.24 crore was recorded due to increased gratuity and leave liabilities from new labour codes. A deferred tax credit of Rs 150 crore was recognized following the company's adoption of the new concessional tax regime. The auditors issued unmodified (clean) opinions on both standalone and consolidated results. During the year, the company acquired the remaining minority shares in Swiss Parenterals and purchased the branded probiotics business from Velbiom Probiotics for Rs 50 crore.
The company delivered robust profit growth exceeding 70%, driven by improved operating margins expanding to 27.11%. The clean audit opinion and dividend declaration are positive signals for shareholders. The large deferred tax credit boosted net profit, though investors should note this is a one-time benefit.